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Abstract
Background: Recent evidence cautions against the use of non-selective beta-blockers (NSBB) in patients with
refractory ascites or spontaneous bacterial peritonitis while other data suggests a survival benefit in patients with
advanced liver disease. The aim of this study was to describe the use and impact of NSBB in patients with cirrhosis
referred for liver transplantation.
Methods: A single-center cohort of patients with cirrhosis, who were referred and evaluated for liver
transplantation between January and June 2012 were studied for baseline characteristics and clinical
outcomes. Patients were grouped according to the use of NSBB at initial evaluation, with the endpoint
of 90-day mortality.
Results: Sixty-five (38%) of 170 consecutive patients evaluated for liver transplantation were taking NSBB.
Patients taking NSBB had higher MELD and Child Pugh score. NSBB use was associated with lower 90-day
mortality (6% vs. 15%) with a risk adjusted hazard ratio of 0.27 (95%CI .09–0.88, p = .03). Patients taking NSBB
developed acute kidney injury (AKI) within 90 days more frequently than patients not taking NSBB (22% vs
11%), p = 0.048). However, this was related to increased stage 1 AKI episodes, all of which resolved. Twelve
(27%) of 45 patients with > 90 day follow up discontinued NSBB, most commonly for hypotension and AKI,
had increased subsequent MELD and mortality.
Conclusions: NSBB use in patients with cirrhosis undergoing liver transplant evaluation is associated with
better short-term survival. Nevertheless, ongoing tolerance of NSBB in this population is dynamic and may
select a subset of patients with better hemodynamic reserve.
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Background
Non-selective beta-blockers (NSBB) play an important
role in primary and secondary prevention of variceal
hemorrhage and are among the most widely used
drugs in patients with cirrhosis [1–3]. They have been
shown to reduce the hepatic venous portal pressure
gradient by decreasing cardiac output and by inducing
splanchnic vasoconstriction mediated by beta-1 and
beta-2 blockade, respectively [4]. In addition, hepatic
venous pressure gradient response to NSBB has been
shown to reduce the risk of developing ascites, refrac-
tory ascites, and hepatorenal syndrome (HRS) [5, 6].
Independent of hemodynamic response, NSBB treat-
ment has also been shown to decrease intestinal per-
meability and bacterial translocation, and to prevent
the development of spontaneous bacterial peritonitis
(SBP), a common and ominous infection in patients
with decompensated cirrhosis [7–9].
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Despite the important role of non-selective beta-
blockers (NSBB) in primary and secondary prevention
of variceal hemorrhage, recent evidence has cautioned
against the use of NSBB in subsets of patients with de-
compensated cirrhosis. The use of NSBB in patients
with cirrhosis with refractory ascites was associated
with increased mortality in one study [10], and
hemodynamic compromise, duration of hospitalization,
and risk of acute kidney injury (AKI) in patients with
SBP [11]. Supporting these concerns is the window hy-
pothesis which suggests that there is a therapeutic win-
dow for NSBB treatment, which closes late in the
natural progression of cirrhosis when a decreased car-
diac compensatory reserve is exacerbated by NSBB with
worsening outcomes [12, 13].
Recent reports however suggest that the use of NSBB
is not uniformly associated with increased mortality in
patients with cirrhosis and refractory ascites [14]. In a
study of patients listed for liver transplantation (LT),
NSBB use was associated with improved survival over a
median follow up of 72 days despite the presence of re-
fractory ascites in over 35% of patients [15]. Addition-
ally, in a nested control study of patients listed for LT,
NSBB use was associated with improved survival in pa-
tients without ascites, but increased AKI (stage≥2) in
those with ascites [16].
Studies examining the use of NSBB in patients with
decompensated cirrhosis are confounded by hetero-
geneity in patient selection, incomplete clinical
characterization, and variability in clinical follow up.
Furthermore, discontinuation of NSBB is not unex-
pected in patients with advanced cirrhosis, but its
clinical correlates have not been characterized. The
balance of risk and benefit of NSBB in patients with
decompensated cirrhosis continues to garner conten-
tion, and the question of continuing or stopping
NSBB therapy in patients referred for LT is clinically
challenging. The aims of this study were to
characterize the use of NSBB in patients with cirrho-
sis referred for LT, and to describe the impact of
NSBB use on short-term mortality and AKI.
Methods
We studied consecutive patients with cirrhosis, 18 years
or older, who were referred and evaluated for LT at In-
diana University between January and June 2012. The
Institutional Review Board at Indiana University School
of Medicine approved this study. Patients were identi-
fied from a prospectively collected transplant database.
Patients with indications for LT other than cirrhosis
were excluded from the study. Patients were grouped
according to NSBB use at the time of initial LT evalu-
ation, as prescribed by their referring physicians. Pa-
tients were followed until death, liver transplantation or
last contact in 2015. The primary endpoint of the study
was 90-day mortality from the time of initial evaluation,
and the secondary outcome was 90-day AKI. The
causes of death and precipitants of AKI were deter-
mined. Other events were also described including;
gastrointestinal bleeding, SBP and LT. We observed
that a significant proportion of patients subsequently
stopped using NSBB during follow-up. We character-
ized patients based on continued NSBB use or discon-
tinuation at a subsequent clinical assessment, at
approximately 3 to 4-month intervals, and described
the associated outcomes.
Study parameters
The following demographic and clinical variables were
recorded: age, gender, race, body mass index in kg/
m2, heart rate in beats/min, systolic blood pressure,
diastolic blood pressure, etiology of cirrhosis, presence
of comorbidities (diabetes mellitus, hypertension,
chronic kidney disease), laboratory data (serum biliru-
bin, albumin, international normalized ratio, creatin-
ine, serum sodium), Child-Pugh score (CPS), Model
for End-Stage Liver Disease (MELD), presence of and
previous bleeding esophageal or gastric varices, pres-
ence and severity of ascites and hepatic encephalop-
athy, transjugular intrahepatic porto-systemic shunt,
other complications of cirrhosis (SBP, hepatorenal
syndrome (HRS), hepatopulmonary syndrome, porto-
pulmonary hypertension, hepatocellular carcinoma),
and AKI incidence and staging as recently defined by
the International Ascites Club [17]. Because evidence
of AKI prior to the initial LT evaluation was less well
documented in referral records, we captured this
event from more readily available hospitalization re-
cords. Refractory ascites was defined as patients re-
quiring multiple therapeutic paracentesis despite
diuretic therapy in the preceding 12 weeks.
Statistical analysis
Statistical analyses were performed using Stata SE15,
(Statacorp LLC., Austin, TX). Continuous variables were
reported as median and inter-quartile range (IQR), and
categorical variables were reported as number and per-
centages. Transplant-free survival analysis was per-
formed using the Kaplan-Meier method. Univariate and
multivariate Competing Risk Regression analyses were
performed to determine predictors of 90-day mortality
and Cox Proportional Hazard Regression analysis for the
development of AKI. Post-hoc analysis included propen-
sity score matching for analysis of risk associated with
NSBB and mortality. We also reported 1-year rates of
mortality and AKI for descriptive purposes.
Due to the potential for NSBB to lower mean arterial
pressure (MAP), MAP was analyzed as a covariate in risk
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modeling. The association of MAP with 90-day mortality
and AKI was also analyzed using the area under the re-
ceiver operator characteristic curve and we tested the
sensitivity and specificity of a MAP threshold of < 82
mmHg, as described by Llach et al. [18], for predicting
mortality and AKI. A p value < 0.05 was considered sta-
tistically significant for all analyses.
Results
Of 170 consecutive patients evaluated for liver trans-
plantation during the study period, 65 (38%) were using
NSBB at the time of initial evaluation, including 36 on
propranolol, 19 on nadolol and 10 on carvedilol
(Additional file 1: Table S1). Patients taking NSBB had
significantly higher MELD (driven by higher INR and
bilirubin), CPS, Child Pugh class, and more frequent
large or previously bleeding esophageal varices (Table 1).
Indications for NSBB included; large or previously bleed-
ing esophageal, gastric or ectopic varices in 42 patients,
small varices with Child B or C in 15, cardiac in 2 pa-
tients and undetermined in 6 patients.
The presence of refractory ascites, SBP and prior
hospitalizations for AKI were similar in patients tak-
ing or not taking NSBB. Although resting heart rate
was lower in patients taking NSBB, MAP was not sig-
nificantly lower. Ninety-day and overall outcomes
from the date of the initial visit for liver transplant
evaluation were compared in patients taking and not
taking NSBB (Table 2). There were no differences in
LT candidacy or transplant rates. Patients taking
NSBB had more frequent episodes of AKI (22% vs.
11%, p = 0.048), attributed to a higher frequency of
stage 1 AKI in patients taking NSBB (p = 0.05). There
was a trend towards more frequent hospitalizations
and SBP, in patients taking NSBB, but the 90-day
rates of these events were similar. Although there was
no significant difference in one-year transplant free
survival, with median follow-up of 282 days (inter-
quartile range 11, 843 days) (Fig. 1a), patients taking
NSBB had a trend towards lower 90-day mortality
(6% vs. 15%, p = 0.06).
Forty-five patients initially taking NSBB had subse-
quent clinical evaluations at median intervals of 113
days (IQR 93–141) from baseline. These patients were
examined for descriptive purposes only given the small
sample size. Discontinuation of NSBB during that time
was associated with increased subsequent MELD and a
trend for increased 90-day mortality (Table 3). Twelve
(27%) patients overall discontinued NSBB, including 6
during hospitalization (for hypotension and AKI in 5,
and unknown reasons in 1), and 6 as outpatients (for
hypotension in 3 and unknown reasons in 3). Patients
who discontinued NSBB had more frequent chronic
kidney disease, but less frequent diabetes mellitus and
hypertension, and lower MAP at baseline (Additional
file 1: Table S2). More patients on propranolol discon-
tinued NSBB during follow up. A comparison of base-
line characteristics based on type of NSBB used was
notable for greater proportion of Child class C in pa-
tients on propranolol and nadolol, and lower MAP (not
reaching statistical significance) in patients on propran-
olol (Additional file 1: Table S1).
The cause of death could be ascertained in 21 patients
who died within 90 days of initial evaluation and was
liver related in all 4 patients on NSBB and in 10 of 17
patients not taking NSBB (p = .2) (Additional file 1:
Table S3). The predictors of all-cause 90-day mortality
are summarized in Table 4. The use of NSBB was inde-
pendently associated with lower 90-day mortality, as
were lower MAP, MELD, and interval AKI (stage ≥2).
The association of NSBB with lower 90-day mortality
persisted in modeling using propensity score matching
for NSBB use at baseline (Additional file 1: Table S4).
There was a trend toward increased AKI in patients
taking NSBB (Fig. 1b). Among 25 patients developing
AKI within 90 days, the precipitating factor was deemed
to be pre-renal in 23 (unknown or non-prerenal causes
in 2 patients). Of these, AKI was related to infection in 3
(23%) of 13 patients taking NSBB and in 5 (50%) of 10
patients not taking NSBB, p = 0.2 (Additional file 1:
Table S5). The course of AKI resulted in renal recovery
in 15 of the 25 patients (6 of 6 (stage 1), 3 of 7 (stage 2),
and 6 of 12 (stage 3) AKI). The median (IQR) serum
creatinine levels (mg/dL) in those recovering renal func-
tion measured pre-AKI, peak-AKI and post-AKI were
1.1 (1–1.3), 2.8 (1.7–4.4) and 1.3 (1–1.6), respectively.
Ten patients with AKI died (4 (stage 2) and 6 (stage 3)
AKI). The predictors of AKI within 90-days are summa-
rized in Table 5. After adjusting for MELD, CPS, and
MAP, NSBB use was not associated with AKI, with
MELD being the only independent predictor.
For descriptive purposes we contrasted outcomes in
the 44 patients with refractory ascites or a history of
SBP, MELD and CPS were similar in patients taking or
not taking NSBB, as were 90-day mortality and AKI
(Additional file 1: Table S6).
Given the expected effect of NSBB on lowering MAP
(lower MAP was associated with increased 90-day
mortality and AKI), we analyzed the relationship of
MAP at baseline with 90-day mortality and AKI using
the area under the receiver operator characteristic
curve (Additional file 1: Table S7). The C-statistic for
MAP and 90-day mortality in all patients was 0.76 (95%
CI, 0.7 to 0.82) (Fig. 2), however the C-statistic was
lower in patients taking NSBB for both mortality and
AKI. A MAP < 82 mmHg was less sensitive and less
specific for predicting these endpoints in patients tak-
ing NSBB. Thirteen (36%) of 36 patients not taking
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Table 1 Comparison of patient characteristics between those taking and not taking NSBB at the initial visit for liver transplant
evaluation. Values are shown as median (interquartile range) or number (percentage)
On NSBB
n = 65
Not on NSBB
n = 105
P value
Age, years 58 (52–64) 59 (53–63) NS
BMI 28 (25–35) 29 (25–35) NS
Male gender 43 (66%) 64 (64%) NS
Diabetes mellitus 21 (32%) 33 (32%) NS
Hypertension 28 (43%) 52 (50%) NS
Chronic kidney disease 16 (25%) 11 (11%) .02
Heart rate beats/min 66 (60–73) 78 (70–88) <.001
Mean arterial pressure, mmHg 82 (76–93) 86 (78–93) NS
Race
Caucasian 57 (88%) 91 (87%) NS
Black 3 (5%) 7 (7%)
Hispanic 4 (6%) 5 (5%)
Other 1 (1%) 2 (2%)
Cirrhosis Etiology
Hepatitis C 27 (42%) 57 (54%) NS
Alcohol 23 (34%) 31 (30%) NS
NASH 20 (30%) 22 (21%) NS
Child Pugh Score 10 (9–11) 9 (7–10) .001
Child Pugh class
A 3 (5%) 16 (15%) .01
B 24 (37%) 50 (48%)
C 38 (58%) 39 (38%)
MELD 16 (14–19) 14 (10–19) 0.03
INR 1.5 (1.3–1.7) 1.3 (1.2–1.6) .04
Bilirubin mg/dL 2.7 (2–3.7) 1.9 (1.3–3.5) .04
Creatinine mg/dL 1.1 (0.8–1.4) 0.9 (0.7–1.2) .1
Albumin g/dL 2.9 (2.5–3.1) 3 (2.5–3.4) NS
Sodium 135 (132–137) 135 (131–138) NS
Esophageal varices
None or small 24 (37%) 70 (71%) <.001
Non-bleeding large 21 (32%) 19 (19%)
Prior bleeding 20 (31%) 13 (13%)
Gastric varices
None or small 61 (94%) 100 (98%) NS
Non-bleeding large 2 (3%) None
Prior bleeding 2 (3%) 2 (2%)
Ascites
None 12 (18%) 30 (30%) NS
Controlled 35 (55%) 53 (51%)
Refractory 18 (27%) 21 (20%)
Hepatic encephalopathy
None 18 (28%) 41 (40%) NS
Controlled 32 (48%) 48 (47%)
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NSBB with a baseline MAP< 82 mmHg died within 90
days, while 3 (5%) of 63 patients with a higher MAP,
p < 0.001. On the other hand, only 3 (9%) of 32 patients
taking NSBB with a MAP< 82 mmHg died within 90
days, and 1 (3%) of 33 with a higher MAP, p = 0.3 (6
patients not on NSBB were missing baseline MAP
values).
Discussion
This study characterized in detail patients with cir-
rhosis evaluated for LT, and 38% were taking NSBB,
as prescribed by their referring providers, with real-
world heterogeneity of types and dosing of these
agents. Although they had more advanced liver dis-
ease by MELD and Child Pugh score, they had para-
doxically better short-term transplant free survival
compared to patients not taking NSBB. Our observa-
tions support those from other centers describing sur-
vival benefit of NSBB use in patients listed for LT
[15, 19]. The role of NSBB in end stage liver disease
and the evidence for potential benefits in decreasing
portal pressure, bacterial translocation and systemic
inflammation are succinctly summarized in a recent
review, and provide a rationale for survival benefit for
NSBB use extending beyond the prevention of variceal
bleeding [20]. Several factors may also contribute to
this finding. Patients not taking NSBB had more fre-
quent non-liver related deaths during follow up. Pa-
tients referred for LT may represent a select group
that received closer clinical follow-up during trans-
plant evaluation (although less than half were listed),
and the relatively high transplant rates at our center
may have minimized risks related to underlying hep-
atic or renal dysfunction.
We contrasted our NSBB using subgroup to cohorts
with reported increased mortality with refractory ascites
treated with propranolol [10]. Notably, NSBB treated pa-
tients in that cohort had worse baseline characteristics
compared with NSBB treated patients in our cohort (re-
fractory/intractable ascites 100% vs. 29%, Child class C,
74% vs. 58%, mean MELD 19 ± 4 vs. 17 ± 5, median
serum sodium 125 vs. 135 mmol/L and median systolic
blood pressure 103 vs. 112 mmHg). Additionally, that
cohort’s median daily propranolol dose was 80 mg, con-
trasting with 20 mg in our propranolol treated patients,
who also had the highest rate of NSBB discontinuation
during follow up. It is important to remember that the
type and dose of NSBB were determined by the referring
physicians and represented the real-world clinical ex-
perience of the cohort. We suspect that patients in our
study were on low doses of propranolol due to limited
hemodynamic reserves, which would also explain their
higher rate of NSBB discontinuation over time.
Few patients in our study had a history of SBP to
meaningfully assess for increased mortality and AKI
with NSBB reported by others [11]. We did not ob-
serve increased 90-day mortality or AKI in patients
taking NSBB when exclusively examining patients
with refractory ascites or a history of SBP. However,
this was a small subgroup, and it is important to note
the significant limitation of diagnosing refractory asci-
tes retrospectively, as in our study. Hence, patients
may be incorrectly categorized as having refractory
ascites and the analysis may be underpowered to de-
tect clinically important differences. This suggests that
even if these contraindications to NSBB therapy are
not absolute, they indicate the need for judicious as-
sessment of NSBB tolerance.
Table 1 Comparison of patient characteristics between those taking and not taking NSBB at the initial visit for liver transplant
evaluation. Values are shown as median (interquartile range) or number (percentage) (Continued)
On NSBB
n = 65
Not on NSBB
n = 105
P value
Refractory 15 (24%) 14 (13%)
Transjugular Intrahepatic Portosystemic shunt 5 (8%) 13 (13%) NS
Cirrhosis complications
Spontaneous bacterial peritonitis 2 (3%) 3 (3%) NS
Hepatorenal syndrome 2 (3%) 3 (3%) NS
Hepatopulmonary syndrome None 2 (2%) NS
Portopulmonary hypertension 2 (3%) 5 (5%) NS
Hepatocellular carcinoma 10 (15%) 26 (26%) NS
Acute kidney injury associated with hospitalization prior to liver transplant evaluation 7 (11%) 13 (13%) NS
NSBB indication
Large or previously bleeding varices 42 (65%) 34 (32%) <.001
NSBB contraindication (refractory ascites or spontaneous bacterial peritonitis) 20 (31%) 24 (23%) NS
Abbreviations: BP blood pressure, MELD model for end-stage liver disease, NSBB non-selective beta blockers, NS not significant
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An important limitation of our and many other studies
is that NSBB use was not randomized but determined by
indications for and tolerance of NSBB, which reflect se-
verity of liver disease and hemodynamic vulnerability, re-
spectively. Similar to a recent report, not all patients
with a history of large or bleeding varices were on NSBB
at the time of initial evaluation [21]. Consequently, pa-
tients tolerating NSBB despite their advanced disease
may represent a self-selected sub-population with better
hemodynamic reserve and arguably better prognosis.
Our analysis of NSBB discontinuation, albeit in a small
subset of patients, led to the main novelty and thrust of
our study. We postulate that this phenomenon may
explain the apparent survival advantage for NSBB use
seen in our and other retrospective studies. In support
of this concept is that NSBB use was not associated with
lower MAP despite higher MELD and CPS. In further
support of this concept, we observed discontinuation of
NSBB during follow up in 27% of patients initially taking
NSBB, with increased subsequent MELD (driven by
renal dysfunction) and a trend for increase mortality.
The lack of transplant-free survival benefit beyond 90-
days with NSBB use at baseline further supports the the-
ory that patients tolerating NSBB are self-selected in this
retrospective study. Since some patients became NSBB
intolerant during follow-up with worse outcomes, it is
Table 2 Clinical outcomes following initial visit for liver transplant evaluation. Values are shown as median (interquartile range) or
number (percentage) unless otherwise described
On NSBB
n = 65
Not on NSBB
n = 105
P value
Liver transplant selection committee discussion 40 (62%) 56 (53%)
List 26 (40%) 34 (32%) NS
Undetermined 7 (11%) 10 (10%)
Denied 7 (11%) 12 (19%)
Duration of follow up (months) 31 (8–64) 23.4 (6–63) NS
Hospitalized within 90 days 18 (28%) 23 (23%) NS
Number of hospitalizations 1 (0–3)
(mean 2.2 ± 2.6)
1 (0–2)
(mean 1.3 ± 1.6)
.06
Acute kidney injury
Overall 28 (43%) 22 (20%) .002
Stage 1 14 (50%) 2 (10%) .009
Stage2 5 (18%) 7 (32%)
Stage 3 9 (32%) 13 (59%)
90-day 14 (22%) 11 (11%) .048
Stage 1 5 (36%)b 1 (9%)b NS
Stage2 3 (21%) 4 (36%)
Stage 3 6 (43%) 6 (55%)
Gastrointestinal bleedinga
Overall 10 (15%) 9 (9%) NS
90-day None None
Spontaneous bacterial peritonitis
Overall 9 (14%) 6 (6%) 0.09
90-day 4 (6%) 2 (2%) NS
Liver transplant
Overall 21 (33%) 32 (31%) NS
90-day 1 (2%) 5 (5%)
Mortality
Overall 32 (49%) 45 (43%) NS
90-day 4 (6%) 16 (15%) .06
Values shown as median (interquartile range) or number (percentage) unless otherwise specified
Abbreviations: NSBB non-selective beta blockers, NS not significant
aRelated to portal hypertension bfor the comparison of stage 1 AKI p = .05
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difficult to ascribe long-term benefit to NSBB use in
our cohort. In other words, rather than being a driver
of better survival, tolerance of NSBB, despite ad-
vanced liver disease, SBP or refractory ascites, may be
a surrogate marker of better hemodynamic reserve,
with that reserve being a plausible reason for better
short-term prognosis. Conversely, patients with ad-
vanced liver disease and intolerance of NSBB (due to
hemodynamic intolerance or AKI in our cohort) may
be a surrogate marker for worse hemodynamic re-
serve and related short-term prognosis.
Hypotension and AKI were the main indications for
stopping NSBB. Notably, NSBB treated patients in our
study were on relatively low doses of the respective agents.
This suggests that the evolution of liver and renal dysfunc-
tion, and hemodynamic vulnerability in these patients is
an important driver of NSBB intolerance and risk of poor
outcomes. These findings are consistent with those of the
Italian Multicentre Project for Propanolol in Prevention of
Bleeding [22] which observed discontinuation of NSBB in
26% of patients due to intolerance. Bossen et al. observed
a 29% rate of NSBB discontinuation in association with in-
creased mortality [23].
Discontinuation of NSBB in our cohort during follow
up may have ameliorated potentially negative effects in
vulnerable patients over time. Overall mortality rates
Fig. 1 a Kaplan-Meier survival curves comparing transplant free survival in patients taking and not taking non-selective beta blocker (NSBB) at the
time of initial liver transplant evaluation (analysis restricted to 365 days after initial evaluation). b Kaplan-Meier survival curves comparing the
incidence of acute kidney injury during follow up in patients taking and not taking non-selective beta blocker (NSBB) (analysis restricted to 365
days after initial evaluation)
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(beyond 90 days) were similar for patients taking and
not taking NSBB, a finding that predominates when
considering recent analyses. A recently published meta-
analysis that included 3 randomized controlled trials,
and a post-hoc analysis of 3 randomized controlled
trials examining NSBB therapy in patients with cirrho-
sis and ascites revealed similar overall survival with or
without NSBB use [14, 23].
Treatment with NSBB may be detrimental to the
hemodynamics of decompensated patients with cirrhosis
Table 3 Comparison of characteristics and outcomes of patients initially taking NSBBs and continuing or discontinuing NSBBs at
subsequent time points following initial visit for liver transplant evaluation. Values shown as median (interquartile range) or number
(percentage). Patients taking stopping NSBB by a median interval of 113 days are compared for clinical parameters at that time and
outcomes in the subsequent 90 days or until the next clinical evaluation. Patients subsequently stopping NSBB before evaluation at
a median interval of 238 days from baseline are compared for clinical parameters at that time and outcomes in the subsequent 90
days
Clinical characteristics Baseline evaluation First clinical re-evaluation
Median 113 days from baseline
n = 45
Second clinical re-evaluation
Median 238 days from baseline
n = 21
NSBB
N = 65
On NSBB
n = 34
Not on NSBB
n = 9
On NSBB
n = 18
Not on NSBB
n = 3
Mean arterial pressure, mmHg 82 (76–93) 89 (75–96) 79 (73–84) 85 (79–96) 87 (69–95)
MELD 16 (14–19) **15 (12–19) **23 (17–27) 14 (12–17) 14 (11–21)
Creatinine (mg/dL) 1.1 (0.8–1.4) *1 (0.8–1.3) *1.8 (1–2.2) 0.9 (0.7–1.3) 0.8 (0.7–1.5)
Child Pugh Score 10 (9–11) 10 (8–11) 11 (10–12) 9 (8–10) 8 (7–12)
NSBB at baseline
Propranolol 36 (56%) **15 (45%) **9 (100%) 7 (35%) 2 (67%)
Nadolol 19 (29%) 12 (35%) None 9 (53%) None
Carvedilol 10 (15%) 7 (20%) None 2 (12%) 1 (33%)
Clinical events occurring after the specified evaluation
Acute kidney injury 14 (21%) 3 (9%) None **None **1 (5%)
Gastrointestinal bleedinga None None None None None
Spontaneous bacterial peritonitis 4 (6%) None None 1 (5%) None
Liver transplant 1 (2%) 6 (18%) 1 (11%) None None
Mortality 4 (8%) *1 (3%) *2 (22%) 1 (5%) None
Lost to follow up None None None 2 (12%) 1 (13%)
Abbreviations: MELD model for end-stage liver disease, NSBB non-selective beta blockers
aRelated to portal hypertension
*p < 0.1 for comparison
**p < 0.05 for comparison
Table 4 Predictors of 90-day mortality in the first 90 days on univariate and multivariate Competing Risk (liver transplant as the
competing risk for mortality) analysis
Univariate Multivariate
Sub-Hazard Ratio
(95% CI)
P value Sub-Hazard Ratio
(95% CI)
P value
MELD 1.2 (1.1–1.3) <.001 1.1 (1.02–1.15) .008
Mean arterial pressure (mmHg) 0.93 (0.89–0.97) <.001 0.95 (0.9–0.99) .03
NSBB use 0.35 (0.12–1.02) .05 0.29 (.09–.95) .04
AKI (≥stage 2) within 90 days 11 (4.7–25.6) <.001 4.4 (1.3–15.4) .02
Child Pugh Score 1.22 (0.99–1.5) .05
Gender (male) 2.6 (0.9–7.8) .09
Factors not predictive of 90-day mortality included; Age, body mass index, race, etiology of liver disease (hepatitis C, alcoholic or non-alcoholic fatty liver disease),
serum albumin and serum sodium or prophylactic antibiotics. Stage 1 AKI was not associated with 90-day mortality and the analysis of AKI within 90-days was
restricted to patients with AKI ≥ stage 2
The results of the final model did not differ when including hospitalization for acute kidney injury prior to liver transplant evaluation
Abbreviations: AKI acute kidney injury, MELD model for end-stage liver disease, NSBB non-selective beta blockers
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who already have a poor circulatory reserve, predis-
posing them to the development of renal impairment
[24–26]. This study provided detailed characterization
of AKI during follow up. While AKI was more fre-
quent in NSBB treated patients, the difference was
wholly attributed to stage 1 episodes, all of which re-
solved. The mortality risk associated with AKI was
only observed in stage ≥2 injuries. Although the risk
adjusted analysis indicated no association for NSBB
use with 90-day AKI (regardless of severity) we noted
more frequent non-infection related pre-renal injuries
in NSBB treated patients, where the hemodynamic ef-
fects of lowering blood pressure may have played a
role in AKI. Hypotension and AKI were also the main
reasons for NSBB discontinuation when documented,
and are in line with the Baveno VI, U.K. and U.S.
guidelines advising caution or discontinuation of
NSBB with renal impairment or hypotension (systolic
blood pressure < 90 mmHg), albeit in patients with re-
fractory ascites [27–29].
Mean arterial pressure at initial evaluation was as in-
dependent predictor of 90-day mortality which supports
previous studies associating low MAP with increased
mortality in patients with cirrhosis and ascites [18, 25].
However, the C-statistic for this association was higher
in patients not using NSBB, and a MAP< 82mmHg was
only discriminating for 90-day mortality in patient not
taking NSBB. It is possible that low MAP on NSBB is re-
lated to the antihypertensive effect of therapy, while low
MAP without NSBB is more reflective of peripheral
vasodilatation and overextended compensatory mecha-
nisms related to advanced liver disease. Hence, the abso-
lute MAP may be less important than the true MAP (off
NSBB) in reflecting an individual’s hemodynamic reserve
and prognosis. These findings support the “window hy-
pothesis” [13], but points to challenges in utilizing a
Table 5 Predictors of acute kidney injury within 90 days of initial liver transplant evaluation visit on univariate and multivariate Cox
Proportional Hazard Regression analysis. The unadjusted hazard ratio for NSBB use and acute kidney injury between 90 and 365 days
of initial evaluation was 0.97, 95% confidence interval 0.4 to 2.7, p = 0.9
Univariate Multivariate
Hazard Ratio
(95% CI)
P value Hazard Ratio
(95% CI)
P value
MELD 1.17 (1.08–1.29) <.001 1.19 (1.07–1.3) .001
Mean arterial pressure (mmHg) 0.96 (.92–1.00) .08
NSBB 3.4 (1.2–9.8) .02
Child Pugh Score 1.44 (1.13–1.83) .003
Factors not predictive of acute kidney injury within 90 days included; NSSB use, age, gender, body mass index, race, etiology of liver disease (hepatitis C, alcoholic
or non-alcoholic fatty liver disease), diabetes mellitus, hypertension and serum albumin and sodium
When analysis was performed for prediction of ≥ stage 2 acute kidney injury within 90 days, the unadjusted hazard ratio for NSBB use was 4.5, 95% CI 0.9–22, p =
0.06, and the adjusted hazard ratio was 0.7, 95% CI 0.08–6.3, p = 0.7 on (adjusted for age, MELD, mean arterial pressure and Childs Pugh score)
Abbreviations: MELD model for end-stage liver disease, NSBB non-selective beta blockers
Fig. 2 The area under the receiver operator characteristic curve for the association of mean arterial pressure at baseline with 90-day mortality
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MAP threshold of 82mmHg to determine closure of the
therapeutic window in patients already taking NSBB. This
also further supports the hypothesis that tolerance of NSBB
may serve as a surrogate marker of more stable liver dis-
ease, better hemodynamic reserve and favorable prognosis.
The limitations of the study include the retrospective
nature, small sample size, heterogeneity in NSBB indica-
tion, type and dosing, missing data, and the risk of afore-
mentioned selection bias. We were not able to elucidate
the reasons for NSBB discontinuation in all cases, and
MAP was based on a single blood pressure measure-
ment. The strengths of the study include the thorough
characterization of patients and clinical outcomes, in-
cluding staging of AKI, and characterization of NSBB
discontinuation during follow up.
Conclusions
In conclusion, NSBB use in patients undergoing LT evalu-
ation was associated with more advanced liver disease but
better short-term survival. NSBB discontinuation was
common and mainly attributed to hypotension and stage
1 AKI. The latter was reversible and not associated with
increased mortality. NSBB tolerance may represent a sur-
rogate marker of more stable liver disease. The potential
interplay of competing effects of NSBB and MAP remains
undefined for guiding optimal use and tolerance of ther-
apy. This study underscores the need for close monitoring
and serial assessment of NSBB tolerance, and highlights
the need for prospective studies to determine the potential
benefits and risks of NSBB therapy in advanced cirrhosis.
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